

1 **Factors Associated with Severe Acute Respiratory Syndrome Coronavirus-2 Infection in Hohoe**  
2 **Municipality, Ghana: A Case-Control Study**

3  
4 Sadat Ibrahim<sup>1,2\*</sup>, Yussif Yakubu<sup>1</sup>, Kwaku Apiagyei<sup>1</sup>, Adjato Franklin Duncan Sylvester<sup>1</sup>, Yahuza Sabit  
5 Tanko<sup>1</sup>, Frank Baiden<sup>1</sup>

6  
7 <sup>1</sup>Department of Epidemiology and Biostatistics, Fred N. Binka School of Public Health, University of  
8 Health and Allied Sciences, Ho, Volta Region, Ghana.

9 <sup>2</sup>KNUST-International Vaccine Institute Collaborative Center, Asante Akim Agogo, Ashanti Region,  
10 Ghana.

11  
12 **\*Corresponding author:**

13 Email: [sadathajjuhas@gmail.com](mailto:sadathajjuhas@gmail.com) (SI)

14  
15 **Abstract**

16 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection was a major public health  
17 challenge globally and in Ghana. To prepare better for future pandemics, an evidence-based understanding  
18 of the determinants of the coronavirus disease is essential to inform public health guidelines and  
19 surveillance. Thus, we identified the factors for SARS-CoV-2 infection in Hohoe Municipality. We  
20 conducted a facility-based, sex and age-matched (1:2) case-control study. Cases were persons with a  
21 laboratory-confirmed SARS-CoV-2 infection by Reverse Transcription Polymerase Chain Reaction (RT-  
22 PCR) or rapid antigen test, while controls tested negative with the same techniques. Data on  
23 sociodemographic, clinical, and exposure-related factors were collected through structured interviews. We  
24 employed a conditional regression model to establish the factors independently associated with SARS-  
25 CoV-2 infection using Stata version 17.0. All statistical tests were two-sided, and a p-value <0.05 was

26 considered statistically significant. A total of 234 participants were enrolled (78 cases, 156 controls). The  
27 mean age of the cases and controls was  $39.7\pm(14.6)$  and  $39.4\pm(14.4)$  years, respectively. Moderate/high  
28 levels of social interaction increased the odds of infection (aOR=3.00, 95% CI:1.05–8.56, p=0.040). Having  
29 no underlying health condition (aOR=0.25, 95% CI:0.09–0.65, p=0.004) and regular physical activity or  
30 exercise (aOR=0.18, 95% CI:0.04–0.70, p=0.014) reduced the risk of infection. Moderate/high level of  
31 social interaction was associated with increased odds of SARS-CoV-2 infection, and having no underlying  
32 condition and frequent exercise/physical activity was protective. Public health interventions should  
33 therefore prioritize strengthening community awareness about the risks of close social interactions and the  
34 benefits of healthy lifestyles, including regular physical activity.

35

36 **Keywords:** Factors, SARS-CoV-2 infection, Hohoe Municipality, Ghana, case-control

## 37 **Introduction**

38           The novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the infectious  
39 agent of the Coronavirus Disease 2019 (COVID-19) pandemic. It caused widespread infection, morbidity,  
40 and mortality since late 2019 and created a global health emergency [1]. On January 30, 2020, the World  
41 Health Organisation (WHO) declared SARS-CoV-2 a public health emergency of international concern,  
42 and a pandemic on March 11, 2020 [1,2]. Ghana's index case was confirmed on March 12, 2020 [3].

43           Due to insufficient testing capacity and a high proportion of asymptomatic infection, the pandemic  
44 swiftly changed, resulting in widespread under-detection and many unaccounted cases [4,5]. Despite the  
45 possibility of symptomatic disease, a significant proportion of the population were asymptomatic carriers,  
46 and clinical presentations ranged from mild to severe or critical [6]. Over 80% of the cases were  
47 asymptomatic or presented with mild symptoms, implying a lot of asymptomatic incubatory and healthy  
48 carriers [2]. This made symptomatic patients a hidden potential source of transmission. Direct or indirect  
49 contact with respiratory aerosols, droplets or other bodily fluids via contaminated surfaces is the known  
50 predominant mode of transmission [7,8].

51           The Centers for Disease Control and Prevention defined risk factors as a variety of factors that  
52 could influence an individual's exposure, or response to a causative agent and increase susceptibility, or  
53 predispose to a disease or infection [9]. Although COVID-19 is mainly transmitted through direct or  
54 indirect exposure to the etiologic agent, transmission dynamics have identified demographics like advanced  
55 age, clinical profiles or cardiovascular diseases, including hypertension and diabetes, and travel history to  
56 predispose to the infection and may account for severe outcomes [10,11]. Moreover, environmental factors  
57 like temperature and humidity, health system organisation and policy, politico-economic situation, large  
58 gatherings, and international travel could substantially drive community transmission [12,13,14]

59           Even with the abundance of epidemiological data produced during the pandemic, significant  
60 knowledge gaps persist regarding the specific factors associated with SARS-CoV-2 infection in rural and  
61 peri-urban African communities. Thus far, no prior studies have established evidence on the determinants

62 of SARS-CoV-2 infection within Hohoe Municipality. We identified the factors for SARS-CoV-2 infection  
63 in Hohoe Municipality. We seek to provide evidence-based insights that can guide surveillance and local  
64 public health interventions and contribute to the broader understanding of SARS-CoV-2 infection  
65 epidemiology in the study setting and Ghana by extension. The results contribute to the larger body of  
66 global health evidence on SARS-CoV-2 disease. Also, it offers implications for informing public health  
67 efforts, strengthening surveillance and pandemic preparedness and response to emerging and reemerging  
68 infectious illnesses.

69

## 70 **Methods**

### 71 **Study Design**

72 We adopted a matched case-control design to identify the factors for SARS-CoV-2 infection. To eliminate  
73 confounders, the cases were individually matched (1 case: 2 controls) to the controls, in which the enrolled  
74 controls were identical to the cases in age ( $\pm 5$  years) and sex.

75

### 76 **Study Site**

77 Hohoe Municipality, with Hohoe as the capital, is where the study was conducted. It was carved out of the  
78 Kpando District and borders the Republic of Togo on the east, on the southeast by the Afadzato district and  
79 southwest by the Kpando Municipality; on the north with the Guan District, and on the northwest with the  
80 Biakoye District. The municipality has a population of 114,472, representing 6.8% of the region's total  
81 population [15]. It comprises 52.1% females and 47.9% males. About fifty-three percent of the population  
82 is urban and comprises eleven major towns/settlements [15]. Regarding healthcare, the municipality has  
83 four sub-districts, the Volta Regional Hospital, six community Health-Based Planning Services  
84 Compounds, and eight health centers. The Volta Regional Hospital is the municipality's largest public  
85 health and referral facility.

## 86 **Study Population**

87 The study was among persons resident in Hohoe Municipality who tested for SARS-CoV-2 by Reverse  
88 transcription polymerase chain reaction (RT-PCR) or rapid antigen test between March 2020 and December  
89 2021. If the test result was positive, the person was classified as a case; otherwise, as a potential control.  
90 Persons aged 18 years or above, and with a positive or negative laboratory-confirmed diagnosis of SARS-  
91 CoV-2 by RT-PCR or antigen test between March 2020 and December 2021 were considered for inclusion.  
92 The exclusion criteria were persons who tested positive for SARS-CoV-2 other than an RT-PCR or rapid  
93 antigen test, tested positive later than December 2021, had previously tested positive for SARS-CoV-2 and  
94 subsequently tested positive again (as potential cases of reinfection), had travelled at the time of data  
95 collection, had debilitating health conditions or poor cognitive ability or incomplete or missing relevant  
96 information in the SARS-CoV-2 infection-line list.

97

## 98 **Sample Size**

99 A priori statistical power calculation using Fleiss with Continuity Correction approach [16] was used to  
100 determine the study's sample size, 237 (79 cases, 158 controls).

101

## 102 **Sampling Method**

103 We employed systematic sampling to recruit the cases using the line list of the cases as a sample frame.  
104 The 79 cases were calculated proportionate to the 506 eligible cases on the line list. The sampling interval  
105 (6<sup>th</sup> term) was determined by dividing the total number of cases (506) by the sample size of the cases (79).  
106 Having determined this, the first case was randomly selected between the first case and the 6<sup>th</sup> term on the  
107 line list. For the controls, the cases were individually matched (1 case: 2 controls) to the controls by age  
108 ( $\pm 5$  years) and sex.

109

110 **Data Collection Procedure**

111 A standard structured questionnaire was used to gather data between September 2, 2023 and October 28,  
112 2023. A face-to-face interview was conducted, and data were captured electronically with KoboCollect.  
113 Written informed consent was obtained from the individual respondents before the questionnaire was  
114 administered.

115

116 **Study Variables**

117 Age, sex, educational level, occupation, marital status, income level, ethnicity, and residence were used to  
118 gather sociodemographic data. Clinical information, SARS-CoV-2 infection contact history, infection  
119 exposure and outcomes were also collected, including self-reported risk information on alcohol use, and  
120 smoking history/status.

121

122 **Statistical Analyses**

123 Data collated on KoboCollect was extracted in Microsoft Excel format. We then checked and resolved all  
124 discrepant data before formal analyses using Stata version 17.0 statistical software. Categorical variables  
125 were described using frequencies and percentages, and the mean (standard deviation) was computed for  
126 continuous variables. Given the individually age- and sex-matched (1:2) case-control design, associations  
127 between potential risk factors and SARS-CoV-2 infection were first explored using univariate conditional  
128 logistic regression, reporting crude odds ratios (cORs) with 95% confidence intervals (CIs). Variables with  
129 a p-value <0.20 in the univariate analyses were considered for inclusion in a multivariable conditional  
130 logistic regression model. Adjusted odds ratios (aORs) with 95% CIs were then estimated to identify factors  
131 independently associated with SARS-CoV-2 infection. All statistical tests were two-sided, and a p-value  
132 <0.05 was considered statistically significant

133

134

135 **Results**

136 **Sociodemographic characteristics of cases and controls**

137 Data was gathered from 234 respondents and the mean ages of the cases and controls were 39.7± (14.6)  
 138 and 39.4± (14.4) years, respectively with an overall mean age of 39.5± (14.5) years (Table 1). Urban  
 139 residence was higher among cases 62 (79.5%) versus controls 94 (60.3%). Less than half of the cases 21  
 140 (26.9%) were asymptomatic as against the controls 89 (57.0%). Of the cases, less than half 33 (42.3%) had  
 141 been prediagnosed with a health condition compared to the controls 108 (69.2%). The proportion of cases  
 142 with hypertension and diabetes was 23 (29.5%) and 18 (23.1%), respectively; versus hypertension 23  
 143 (14.7%) and diabetes 21 (13.5%) in the control group.

144

145 **Table 1: Sociodemographic characteristics of cases and controls**

<b>Variable</b>	<b>Case (78) n (%)</b>	<b>Control (156) n (%)</b>	<b>Total (234) n (%)</b>
<b>Mean age ± (SD)</b>	39.7 (14.6)	39.4 (14.4)	39.5 (14.5)
<b>Age</b>			
≤30	28 (35.9)	53 (34.0)	81 (34.6)
≥31	50 (64.1)	103 (66.0)	153 (65.4)
<b>Sex</b>			
Male	40 (51.3)	80 (51.3)	120 (51.3)
Female	38 (48.7)	76 (48.7)	114 (48.7)
<b>Highest educational level</b>			
None	5 (6.4)	15 (9.6)	20 (8.5)
Primary	1 (1.3)	21 (13.5)	22 (9.4)
Junior High School	11 (14.1)	33 (21.1)	44 (18.8)
Senior High School	21 (26.9)	31 (19.9)	52 (22.2)
Tertiary/post-secondary	40 (51.3)	56 (35.9)	96 (41.0)
<b>Occupation</b>			
Unemployed	21 (26.9)	43 (27.6)	64 (27.4)
Formal	28 (35.9)	35 (22.4)	63 (26.9)
Informal/Self-employed	29 (37.2)	78 (50.0)	107 (45.7)
<b>Marital status</b>			
Single	29 (37.2)	55 (35.3)	84 (35.9)
Married	47 (60.3)	83 (53.2)	130 (55.6)
Divorced/widowed	2 (2.6)	18 (11.5)	20 (8.5)
<b>Income level</b>			
High	7 (9.0)	18 (11.5)	25 (10.7)
Low	4 (4.1)	23 (14.7)	27 (11.5)
Middle	67 (85.9)	115 (73.7)	182 (77.8)
<b>Residence</b>			
Rural	16 (20.5)	62 (39.7)	78 (33.3)

Urban	62 (79.5)	94 (60.3)	156 (66.7)
<b>COVID-19 symptom classification</b>			
Asymptomatic	21 (26.9)	89 (94.9%)	110 (47.0)
Symptomatic	57 (73.1)	67 (43.0)	124 (53.0)
<b>Ever been diagnosed with a health condition</b>			
No	45 (57.7)	48 (30.8)	93 (39.7)
Yes	33 (42.3)	108 (69.2)	141 (60.3)
<b>Hypertension</b>			
No	55 (70.5)	133 (85.3)	188 (80.3)
Yes	23 (29.5)	23 (14.7)	46 (19.7)
<b>Diabetes</b>			
No	60 (76.9)	135 (86.5)	195 (83.3)
Yes	18 (23.1)	21 (13.5)	39 (16.7)
<b>Smoking status prior to testing</b>			
Non-smoker	<b>62 (79.5)</b>	138 (88.5)	200 (85.5)
Smoker	<b>16 (20.5)</b>	18 (11.5)	34 (14.5)
<b>Substance use prior to testing</b>			
Current user	27 (34.6)	25 (16.0)	52 (22.2)
Former user	51 (65.4)	131 (84.0)	182 (77.8)

146

147

#### 148 **Contact History and Disease Exposure of Cases and Controls**

149 Table 2 illustrates the contact history and disease exposure of the respondents. Among the cases, the  
 150 majority 47 (60.3%) attended a gathering of less than ten people, and a greater 54 (69.2%) proportion  
 151 travelled within Ghana. Most 65 (83.3%) of the cases had a moderate/high level of frequent social  
 152 interactions compared to 82 (52.6%) of the controls.

153

#### 154 **Table 2: Contact History and Disease Exposure of Cases and Controls**

Variable	Case (78) <i>n</i> (%)	Control (156) <i>n</i> (%)	Total (234) <i>n</i> (%)
<b>Lived in a densely populated or crowded area prior to testing</b>			
No	55 (70.5)	123 (78.8)	178 (76.1)
Yes	23 (29.5)	33 (21.2)	56 (23.9)
<b>Attended a mass gathering prior to testing</b>			
No	43 (55.1)	95 (60.9)	138 (59.0)
Yes	35 (44.9)	61 (39.1)	96 (41.0)
<b>Attended a gathering of fewer than ten people prior to testing</b>			
No	31 (39.7)	92 (59.0)	123 (52.6)
Yes	47 (60.3)	64 (41.0)	111 (47.4)

<b>Travelled to a place within Ghana</b>			
No	24 (30.8)	98 (62.8)	122 (52.1)
Yes	54 (69.2)	58 (37.2)	112 (47.9)
<b>Travel location</b>			
Rural	14 (25.9)	25 (43.9)	39 (35.1)
Urban	40 (74.1)	32 (56.1)	72 (64.9)
<b>Visited a healthcare facility prior to testing</b>			
No	34 (43.6)	103 (66.0)	137 (58.6)
Yes	44 (56.4)	53 (34.0)	97 (41.4)
<b>Had close contact with a suspected or confirmed COVID-19 case prior to testing</b>			
No	63 (80.8)	146 (93.6)	209 (89.3)
Yes	15 (19.2)	10 (6.4)	25 (10.7)
<b>Had close contact with a generally ill person prior to testing</b>			
No	58 (74.4)	146 (93.6)	204 (87.2)
Yes	20 (25.6)	10 (6.4)	30 (12.8)
<b>Usual/most frequent means of transportation prior to testing</b>			
Private means	18 (23.1)	53 (34.0)	71 (30.3)
Public means	60 (76.9)	103 (66.0)	163 (69.7)
<b>Level of frequent social interactions prior to testing</b>			
Low crowding	13 (16.7)	82 (52.6)	95 (40.6)
Moderate/high crowding	65 (83.3)	74 (47.4)	139 (59.4)
<b>Place of most possible exposure</b>			
<b>Health facility</b>			
No	59 (75.6)	146 (93.9)	205 (87.6)
Yes	19 (24.4)	10 (6.4)	29 (12.4)
<b>Workplace</b>			
No	59 (75.6)	111 (71.2)	170 (72.6)
Yes	19 (24.4)	45 (28.8)	64 (27.4)
<b>Had access to PPE</b>			
No	30 (38.5)	56 (35.9)	86 (36.7)
Yes	48 (61.5)	100 (64.1)	148 (63.3)

155

156

157 **Univariate and Conditional Multivariate Logistic Regression Analyses of Severe Acute Respiratory**  
 158 **Syndrome Coronavirus-2 Infection Risk Factors.**

159 Univariate logistic regression analysis displayed in Table 4 revealed several factors statistically associated  
 160 with SARS-CoV-2 infection. These included household residence type (cOR=0.55, 95% CI: 0.31-0.95,  
 161 p=0.032), symptom classification (cOR=3.57, 95% CI: 1.92-6.63, p<0.001), number of children  
 162 (cOR=0.33, 95% CI: 0.11-0.96, p=0.042), physical activity (cOR=0.17, 95% CI: 0.06-0.45, p<0.004),  
 163 gathering of less than ten people (cOR=2.13, 95% CI: 1.22-3.71, p<0.008), and level of social interaction  
 164 (cOR=5.82, 95% CI: 2.80-12.11, p<0.001). Additionally, a health facility as a possible place of exposure  
 165 (cOR=4.85, 95% CI: 2.02-11.63, p<0.001) showed an association. NHIS status (cOR=1.93, 95% CI: 1.00-  
 166 3.74, p=0.050) was borderline statistically significant.

167 In the conditional multivariate model, moderate/high social interaction was associated with higher odds of  
 168 SARS-CoV-2 infection (aOR 3.00, 95% CI 1.05–8.56). Absence of an underlying condition (aOR 0.25,  
 169 95% CI 0.09–0.65) and regular physical activity (aOR 0.18, 95% CI 0.04–0.70) were associated with lower  
 170 odds. Associations for attending small gatherings and recent travel were elevated in crude analyses but were  
 171 not statistically significant after adjustment.

172 **Table 3: Univariate and multivariate logistic regression analyses of predictors for SARS-CoV-2**  
 173 **Infection**

Variable	cOR (95% CI)	p-value	aOR (95% CI)	p-value
<b>Residence</b>				
Rural	Ref.		Ref.	
Urban	<b>2.44 (1.30-4.60)</b>	<b>0.006</b>	1.16 (0.45-3.03)	0.758
<b>Household residence type</b>				
Compound house setting	Ref.		Ref.	
Private/self-contained	<b>0.55 (0.31-0.95)</b>	<b>0.032</b>	0.57 (0.25-1.30)	0.182
<b>National Health Insurance Scheme (NHIS) status prior to testing</b>				
Inactive	Ref.		Ref.	
Active	<b>1.93 (1.00-3.74)</b>	<b>0.050</b>	1.51 (0.52-4.37)	0.447
<b>Symptom classification</b>				
Asymptomatic	Ref.		Ref.	
Symptomatic	<b>3.57 (1.92-6.63)</b>	<b>&lt;0.001</b>	2.21 (0.90-5.41)	0.082
<b>Number of children had prior to testing</b>				

	None	Ref.		Ref.	
	≥1	<b>0.33 (0.11-0.96)</b>	<b>0.042</b>	0.21 (0.03-1.37)	0.103
<b>Diagnosed with underlying health condition(s) prior to testing</b>					
	No	<b>0.25 (0.13-0.50)</b>	<b>&lt;0.001</b>	<b>0.25 (0.09-0.65)</b>	<b>0.004</b>
	Yes	Ref.		Ref.	
<b>Engaged in physical activities or exercises regularly prior to testing</b>					
	No	Ref.		Ref.	
	Yes	<b>0.17 (0.06-0.45)</b>	<b>&lt;0.004</b>	<b>0.18 (0.04-0.70)</b>	<b>0.014</b>
<b>Attended gathering with less than ten people prior to testing</b>					
	No	Ref.		Ref.	
	Yes	<b>2.13 (1.22-3.71)</b>	<b>0.008</b>	2.13 (0.87-5.18)	0.097
<b>Travelled to another region, town or place prior to testing</b>					
	No	Ref.		Ref.	
	Yes	<b>3.42 (1.92-6.07)</b>	<b>&lt;0.007</b>	2.17 (0.92-5.10)	0.076
<b>Visited a healthcare facility prior to testing</b>					
	No	Ref.		Ref.	
	Yes	<b>2.57 (1.44-4.58)</b>	<b>0.001</b>	1.86 (0.73-4.76)	0.195
<b>Had close contact with a suspected or confirmed COVID-19 case prior to testing</b>					
	No	Ref.		Ref.	
	Yes	<b>3.72 (1.50-9.24)</b>	<b>0.005</b>	0.64 (0.12-3.33)	0.598
<b>Had close contact with a generally ill person prior to testing</b>					
	No	Ref.		Ref.	
	Yes	<b>4.30 (1.95-9.46)</b>	<b>&lt;0.001</b>	1.16 (0.30-4.43)	0.832
<b>Level of frequent social interactions prior to testing</b>					
	Low crowding	Ref.		Ref.	
	Moderate/high crowding	<b>5.82 (2.80-12.11)</b>	<b>&lt;0.001</b>	<b>3.00 (1.05-8.56)</b>	<b>0.040</b>
<b>Health facility</b>					
	No	Ref.		Ref.	
	Yes	<b>4.85 (2.02-11.63)</b>	<b>&lt;0.001</b>	1.51 (0.26-8.65)	0.645

174 *aOR – Adjusted Odds Ratio, cOR – Crude Odds Ratio, CI – Confidence Interval*

175 *\*Boldface type indicates a statistically significant difference at  $p < 0.05$*

176

177

178

## 179 **Discussion**

180 Numerous studies have demonstrated factors that facilitate susceptibility or predisposition to  
181 COVID-19. There is a clear link between certain pre-existing health conditions and SARS-CoV-2 infection  
182 and its adverse prognosis [17]. This study found hypertension and diabetes to be the prevalent comorbid  
183 conditions, which are not different from findings reported by [18,19,20,21]. Our study showed a syndemic  
184 relationship between SARS-CoV-2 infection and preexisting health conditions. A similar study [21]  
185 demonstrated that comorbidity emerged statistically significant with SARS-CoV-2 infection. Additionally,  
186 in support, [22] reported that SARS-CoV-2 infection was predominant among people who presented with  
187 a comorbidity. Furthermore, the outcome of a national study in Saudi Arabia disclosed that a high  
188 proportion of the COVID-19 patients had a history of at least one lifelong illness, which seemingly supports  
189 this study's finding [23]. On account of the evidence from the above studies, whose findings corroborate  
190 that of our study, it is imperative to consider and tailor actions that will safeguard the health needs of persons  
191 with a preexisting diagnosis. Individuals with a longstanding illness tend to face severe or critical clinical  
192 outcomes or even death. Our findings imply that further studies are vital to assess the clinical outcomes of  
193 SARS-CoV-2 infection cases in the study jurisdiction.

194 Epidemiological link is crucial to understanding SARS-CoV-2 infection transmission dynamics,  
195 spread and evidence-based control actions. The current study established that attendance at small gatherings  
196 showed an increased risk, but was however, not statistically significant in the in the final multivariate model.  
197 Inversely, this finding is on par with [18,24] which reported that attending a mass social gathering was  
198 associated with SARS-CoV-2 infection. Small gatherings create a perceived sense of safety leading to more  
199 relaxed precautions and preventive behaviors such as mask use, physical distancing and attention to  
200 ventilation. This false sense of security could facilitate transmission. Moreover, such gatherings typically  
201 occur in indoor settings where airflow is limited and individuals remain in proximity for extended periods.  
202 In contrast, larger gatherings, which have been more strictly regulated or subject to formal preventive  
203 protocols during the pandemic may have entailed greater adherence to public health guidelines.

204 Regular physical activity has been associated with enhanced immune function, which contributes  
205 to a strengthened immune system, potentially reducing the severity and duration of SARS-CoV-2 infection  
206 [25,26]. Our study uncovered that regular exercise or physical activity decreased the risk of SARS-CoV-2  
207 infection. A similar finding reported by [21] indicated that physical exercise or activity lessened the odds  
208 of infection. In support of the above assertions, a study in the United States revealed a negative correlation  
209 between physical activity and SARS-CoV-2 infection further showing a worse prognosis of death among  
210 those whose physical activity was less. [27]. Moreover, according to [28], adults between the ages of 40  
211 and 69, those who were physically active were less likely to be confirmed SARS-CoV-2 seropositive.  
212 However, in dissonance with the findings aforementioned, [29] found that physical activity was not  
213 associated with the risk of SARS-CoV-2 infection. Similarly, it was also conversely reported that physical  
214 activity had no protective association between SARS-CoV-2 infection and its related symptoms [30].  
215 Physical inactivity predisposes to longstanding diseases like hypertension and diabetes, which are  
216 established comorbidities that increase SARS-CoV-2-infection susceptibility or severity and point out the  
217 significance of regular physical activity and exercise in SARS-CoV-2 infection prevention [30]. Although  
218 it is widely asserted that regular physical activity is a non-pharmacological intervention against SARS-  
219 CoV-2 infection and could help alleviate the symptoms and severity [31], there is uncertainty regarding the  
220 effects on SARS-CoV-2-infected individuals, despite some evidence to the effect that physical exercise  
221 improves respiratory and physical health.

## 222 **Strengths and Limitations**

223 This study provides localised evidence for guiding tailored public health interventions and contributes to  
224 the broader understanding of SARS-CoV-2 epidemiology. A major strength of this study is the use of a  
225 matched case-control design, which effectively controlled for major confounders, thereby enhancing the  
226 internal validity of the identified associations. Nonetheless, certain limitations must be acknowledged. A  
227 notable limitation was the potential of recall bias which may have stemmed from respondents' inability to  
228 accurately recall or report their exposure history or conditions, as the study was carried out long after the

229 pandemic (time lag between exposure (2020–2021) and data collection (2023)). Second, the study might  
230 have been prone to social desirability bias in the reporting of preventive behaviors. Particularly, cases may  
231 have overestimated adherence to preventive behaviors and protocols which could result in weak or reverse  
232 true associations. However, the use of a standard and validated closed-ended questionnaire was used to  
233 improve respondents' information. Lastly, missing information such as contact address in the line list  
234 records may have introduced some selection bias during sampling.

## 235 **Conclusion**

236 This study identified moderate to high levels of social interaction as the main risk factor for SARS-CoV-2  
237 infection, while regular physical activity and the absence of preexisting health conditions were protective.  
238 These findings reinforce the importance of maintaining safe social behaviors during outbreaks and highlight  
239 the role of individual health status in susceptibility to infection. Public health interventions should therefore  
240 prioritize strengthening community awareness about the risks of close social interactions and the benefits  
241 of healthy lifestyles, including regular physical activity. Moreover, tailored strategies should be developed  
242 to protect individuals with underlying health conditions, who remain particularly vulnerable. Lessons from  
243 this study provide important insights for strengthening preparedness and response strategies against future  
244 pandemics in Ghana and similar settings. Further research is needed to explore the long-term effects of  
245 these risk and protective factors on SARS-CoV-2 infection outcomes.

## 246 **Acknowledgement**

247 The authors gratefully acknowledge the Hohoe Municipal Director of Health Services, the Disease Control  
248 Officers of the Hohoe District Health Directorate and all individuals whose cooperation and invaluable  
249 contributions in various capacities made this work possible.

250

251

252

253 **Authors' contributions**

254 Conceptualization and writing official draft: S.I., and F.B., Data collection: S.I., Y.Y., Y.S.T., and K.A,  
255 Data Curation and formal Analyses: S.I., A.F.D.S, Y.S.T and Y.Y., Editing and final review: F.B., Y.Y.,  
256 K.A. All authors read and approved the current version of the manuscript.

257 **Abbreviations**

258 COVID-19: Coronavirus Disease

259 RT-PCR: Reverse transcription polymerase chain reaction

260 SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2

261 WHO: World Health Organization

262 **Declarations**

263 **Availability of data and materials**

264 The anonymized dataset will be deposited in an open repository.

265 **Ethical Considerations**

266 The study protocol was approved by the University of Health and Allied Sciences Research Ethics  
267 Committee (approval ID: *UHAS-RECA.8[88]22-23*) and the Ghana Health Service Ethics Review  
268 Committee (approval ID: *GHS-ERC:029/06/23*).

269

270 **Competing interests**

271 The authors declare that the study was carried out without any potential conflicts of interest.

272

273 **Funding**

274 The authors received no support for the conduct of the study and/ or publication of this work.

## 275 **References**

- 276 1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical  
277 characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan,  
278 China. *jama*. 2020 Mar 17;323(11):1061-9. <https://doi.org/10.1001/jama.2020.1585>
- 279 2. World Health Organization. Coronavirus disease (COVID-19) pandemic. A timeline of WHO's  
280 COVID-19 Response in the WHO European Region: a living document. WHO Regional Office for  
281 Europe. 2022. WHO/EURO:2022-1772-41523-63024.
- 282 3. Ghana Health Service COVID-19 Situation Dashboard. Ghana COVID-19 Updates. 2023.  
283 <https://www.ghanahealthservice.org/covid19/archive.php>.
- 284 4. Odikro MA, Kenu E, Malm KL, Asiedu-Bekoe F, Noora CL, Frimpong J, Calys-Tagoe B, Koram KA.  
285 Epidemiology of COVID-19 outbreak in Ghana, 2020. *Ghana Medical Journal*. 2020 Dec 31;54(4s):5-  
286 15. <http://dx.doi.org/10.4314/gmj.v54i4s.3>
- 287 5. Likassa HT, Xain W, Tang X, Gobebo G. Predictive models on COVID 19: What Africans should do?.  
288 *Infectious Disease Modelling*. 2021 Jan 1;6:302-12. <https://doi.org/10.1016/j.idm.2020.10.015>
- 289 6. Yawson AE, Oduro-Mensah E, Tetteh J, Adomako I, Adjei-Mensah E, Owoo C, Yawson AO, Oliver-  
290 Commey JA, Pupilampu P, Samba A, Lartey M. Clinical features of COVID-19 in Ghana:  
291 symptomatology, illness severity and comorbid non-communicable diseases. *Ghana Medical Journal*.  
292 2020 Dec 31;54(4s):23-32. <https://doi.org/10.4314/gmj.v54i4s.5>
- 293 7. Rashedi J, Mahdavi Poor B, Asgharzadeh V, Pourostadi M, Samadi Kafil H, Vegari A, Tayebi-  
294 Khosroshahi H, Asgharzadeh M. Risk factors for COVID-19. *Infez Med*. 2020 Dec 1;28(4):469-74.
- 295 8. World Health Organization. COVID-19 case definitions [Internet]. Geneva: World Health  
296 Organization; 2020 [cited 2025 Aug 11].[https://iris.who.int/bitstream/handle/10665/360579/WHO-](https://iris.who.int/bitstream/handle/10665/360579/WHO-2019-nCoV-Surveillance-Case-Definition-2022.1-eng.pdf?sequence=1)  
297 [2019-nCoV-Surveillance-Case-Definition-2022.1-eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/360579/WHO-2019-nCoV-Surveillance-Case-Definition-2022.1-eng.pdf?sequence=1)
- 298 9. Centers for Disease Control. Coronavirus disease 2019 (COVID-19) transmission, risk factors,  
299 prevention and control: a minireview. *J Infect Dis Epidemiol* [Internet]. 2021 [cited 2025 Aug  
300 11];6(4):1-5. <https://doi.org/10.23937/2474-3658/1510145>

- 301 10. Gesesew HA, Koye DN, Fetene DM, Woldegiorgis M, Kinfu Y, Geleto AB, Melaku YA, Mohammed  
302 H, Alene KA, Awoke MA, Birhanu MM. Risk factors for COVID-19 infection, disease severity and  
303 related deaths in Africa: a systematic review. *BMJ open*. 2021 Feb 1;11(2):e044618.  
304 <http://dx.doi.org/10.1136/bmjopen-2020-044618>
- 305 11. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, Andrews N, Byford R,  
306 Dabrera G, Elliot A, Ellis J. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College  
307 of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional  
308 study. *The Lancet Infectious Diseases*. 2020 Sep 1;20(9):1034-42. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(20)30371-6)  
309 [3099\(20\)30371-6](https://doi.org/10.1016/S1473-3099(20)30371-6)
- 310 12. Richard A, Wisniak A, Perez-Saez J, Garrison-Desany H, Petrovic D, Piumatti G, Baysson H, Picazio  
311 A, Pennacchio F, De Ridder D, Chappuis F. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk  
312 factors for infection and associated symptoms in Geneva, Switzerland: a population-based study.  
313 *Scandinavian journal of public health*. 2022 Feb;50(1):124-35.  
314 <https://doi.org/10.1177/14034948211048050>
- 315 13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features  
316 of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet*. 2020 Feb  
317 15;395(10223):497-506. [https://doi.org/10.1016/s0140-6736\(20\)30183-5](https://doi.org/10.1016/s0140-6736(20)30183-5)
- 318 14. Awosolu O, Oladele O. Coronavirus Disease 2019 (COVID-19) Transmission, Risk Fac-tors.  
319 Prevention and Control: A Minireview. *J Infect Dis Epidemiol*. 2020;6:145.  
320 <https://doi.org/10.23937/2474-3658/1510145>
- 321 15. Ghana Statistical Service. 2021 Population and Housing Census: Preliminary Report.  
322 Volume1,GSS.2023.[https://statsghana.gov.gh/gssmain/fileUpload/pressrelease/2021%20PHC%20Ge](https://statsghana.gov.gh/gssmain/fileUpload/pressrelease/2021%20PHC%20General%20Report%20Vol%203A_Population%20of%20Regions%20and%20Districts_181121.pdf)  
323 [neral%20Report%20Vol%203A\\_Population%20of%20Regions%20and%20Districts\\_181121.pdf](https://statsghana.gov.gh/gssmain/fileUpload/pressrelease/2021%20PHC%20General%20Report%20Vol%203A_Population%20of%20Regions%20and%20Districts_181121.pdf)
- 324 16. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. john wiley & sons; 2013  
325 Jun 12.

- 326 17. Oduro-Mensah E, Yawson AE, Tetteh J, Adomako I, Adjei-Mensah E, Owoo C, Yawson AO, Oliver-  
327 Commey JA, Puplampu P, Samba A, Lartey M. Clinical features of COVID-19 in Ghana:  
328 symptomatology, illness severity and comorbid non-communicable diseases. *Ghana Medical Journal*.  
329 2020 Dec 31;54(4s):23-32. <https://doi.org/10.4314%2Fgmj.v54i4s.5>
- 330 18. Utulu R, Ajayi IO, Bello S, Balogun MS, Madubueze UC, Adeyemi IT, Omoju OT, Adeke AS,  
331 Adenekan AO, Iyare O. Risk factors for COVID-19 infection and disease severity in Nigeria: a case-  
332 control study. *Pan African Medical Journal*. 2022 Apr 20;41(1).  
333 <https://doi.org/10.11604/pamj.2022.41.317.34307>
- 334 19. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2  
335 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.  
336 *International journal of antimicrobial agents*. 2020 Mar 1;55(3):105924.  
337 <https://doi.org/10.1016/j.ijantimicag.2020.105924>
- 338 20. Shah H, Khan MS, Dhurandhar NV, Hegde V. The triumvirate: why hypertension, obesity, and diabetes  
339 are risk factors for adverse effects in patients with COVID-19. *Acta diabetologica*. 2021 Jul;58(7):831-  
340 43. <https://doi.org/10.1007/s00592-020-01636-z>
- 341 21. Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C, Ferguson LD, Berry  
342 C, Mackay DF, Gill JM, Pell JP. Modifiable and non-modifiable risk factors for COVID-19, and  
343 comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort  
344 study. *BMJ open*. 2020 Nov 1;10(11):e040402. <https://doi.org/10.1136/bmjopen-2020-040402>
- 345 22. Shahbazi F, Solgi M, Khazaei S. Predisposing risk factors for COVID-19 infection: A case-control  
346 study. *Caspian Journal of Internal Medicine*. 2020;11(Suppl 1):495.  
347 <https://doi.org/10.22088/cjim.11.0.495>
- 348 23. Alhumaid S, Al Mutair A, Al Alawi Z, Al Salman K, Al Dossary N, Omar A, Alismail M, Al Ghazal  
349 AM, Jubarah MB, Al Shaikh H, Al Mahdi MM. Clinical features and prognostic factors of intensive  
350 and non-intensive 1014 COVID-19 patients: an experience cohort from Alahsa, Saudi Arabia. *European*  
351 *Journal of Medical Research*. 2021 May 24;26(1):47. <https://doi.org/10.1186/s40001-021-00517-7>

- 352 24. Graff K, Smith C, Silveira L, Jung S, Curran-Hays S, Jarjour J, Carpenter L, Pickard K, Mattiucci M,  
353 Fresia J, McFarland EJ. Risk factors for severe COVID-19 in children. *The Pediatric infectious disease*  
354 *journal*. 2021 Apr 1;40(4):e137-45. <https://doi.org/10.1097/inf.0000000000003043>
- 355 25. Castoldi RC, de Ângelo JC, Pereira TT, Dias RM, Negrão FJ. Relationship between physical exercise  
356 and COVID-19 (SARS-CoV-2): Systematic review. *Sport sciences for health*. 2023 Mar;19(1):55-67.  
357 <https://doi.org/10.1007/s11332-022-01028-6>
- 358 26. Wang J, Sato T, Sakuraba A. Worldwide association of lifestyle-related factors and COVID-19  
359 mortality. *Annals of medicine*. 2021 Jan 1;53(1):1531-6.  
360 <https://doi.org/10.1080/07853890.2021.1968029>
- 361 27. Cunningham GB. Physical activity and its relationship with COVID-19 cases and deaths: Analysis of  
362 US counties. *Journal of sport and health science*. 2021 Sep 1;10(5):570-  
363 <https://doi.org/10.1016/j.jshs.2021.03.008>
- 364 28. Zhang X, Li X, Sun Z, He Y, Xu W, Campbell H, Dunlop MG, Timofeeva M, Theodoratou E. Physical  
365 activity and COVID-19: an observational and Mendelian randomisation study. *Journal of global health*.  
366 2020 Dec 6;10(2):020514. <https://doi.org/10.7189/jogh.10.020514>
- 367 29. Yeo TJ. Sport and exercise during and beyond the COVID-19 pandemic. *European journal of*  
368 *preventive cardiology*. 2020 Aug;27(12):1239-41. <https://doi.org/10.1177/2047487320933260>
- 369 30. Karacop E, Ozdemir R. Since January 2020 Elsevier has created a COVID-19 resource centre with free  
370 information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource  
371 centre is hosted on Elsevier Connect, the company's public news and information website. *Journal of*  
372 *Electrocardiology*. 2020;62:59-64.  
373 <https://doi.org/10.1016/j.jsams.2020.10.009>
- 374 31. Mohamed AA, Alawna M. The effect of aerobic exercise on immune biomarkers and symptoms  
375 severity and progression in patients with COVID-19: A randomized control trial. *Journal of bodywork*  
376 *and movement therapies*. 2021 Oct 1;28:425-32. <https://doi.org/10.1016/j.jbmt.2021.07.012>

377